Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Kroger CEO McMullen resigns after personal conduct probe

(Sharecast News) - US supermarket chain Kroger said on Monday that chairman and chief executive Rodney McMullen has resigned after a board investigation found that his personal conduct was "inconsistent" with the company's "policy on business ethics". Lead director Ronald Sargent will serve as chairman and interim CEO with immediate effect, while Mark Sutton will become Kroger's lead independent director, also effective immediately.

Kroger said that on 21 February, it was made aware of "certain personal conduct" by McMullen and immediately retained outside independent counsel to conduct an investigation, which was overseen by a special board committee.

It pointed out that McMullen's conduct is not related to the company's financial performance, operations or reporting, and did not involve any Kroger associates.

Sargent, who has been a Kroger director since 2006 and has served as the lead director of Kroger since 2017, spent the first ten years of his professional career at Kroger, working in several roles across stores, sales, marketing, manufacturing and strategy.

He is a veteran retail operator and leader with 35 years of experience, including as the chairman and CEO of Staples from 2002 to 2016 after joining the company in 1989.

He currently serves on the board of Wells Fargo & Company, where he is chair of the Human Resources Committee, and the board of Five Below.

Kroger said it expects full-year identical sales without fuel to be at the high end of its guidance range and full-year adjusted earnings per share to be slightly above the high end of its guidance range.

The company is due to report fourth-quarter and full-year 2024 results on 6 March.

At 1520 GMT, the shares were down 1.3% at $63.96.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.